Technetium (99mTc) nofetumomab merpentan
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Mouse |
| Clinical data | |
| Trade names | Verluma |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 10.5 hours |
| Excretion | renal (64%) |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| (what is this?) (verify) | |
Technetium (99mTc) nofetumomab merpentan (trade name Verluma) is a mouse monoclonal antibody derivative used in the diagnosis of lung cancer,[1] gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma.[2] The antibody part, nofetumomab, is attached to the chelator merpentan, which links it to the radioisotope technetium-99m (99mTc).[3]
- ^ Straka MR, Joyce JM, Myers DT (January 2000). "Tc-99m nofetumomab merpentan complements an equivocal bone scan for detecting skeletal metastatic disease from lung cancer". Clinical Nuclear Medicine. 25 (1): 54–5. doi:10.1097/00003072-200001000-00013. PMID 10634533.
- ^ Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL (September 1997). "Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy". Clinical Nuclear Medicine. 22 (9): 615–20. doi:10.1097/00003072-199709000-00007. PMID 9298295.
- ^ "International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). Geneva: World Health Organization. 2002. Archived from the original (PDF) on July 3, 2011.